Clinical Trial Update: Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating irinotecan and docetaxel with or without cetuximab in metastatic pancreatic cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-07-19